Abstract
The searches identified 580 papers (Fig. 115.1). However, only ten mapped to the search terms and eligibility criteria. The current systematic reviews were also examined to gain further knowledge about the subject. Five hundred and eighty papers were excluded due to not conforming to eligibility criteria or adding to the evidence for psychosexual pathways or components of pathways for men with prostate cancer, post-surgery. Results were presented as per PRISMA criteria [1]. Of the ten papers left, relevant abstracts were identified and the full papers obtained (all of which were in English), to quality assure against criteria. There was significant heterogeneity within studies, including clinical topic, numbers, outcomes, as a results a narrative review was thought to be best.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Online). 2009;339:332–6.
Thomas R, Williams M, Bellamy P. A polyphenol rich whole food supplement reduces PSA progression in men with prostate cancer in a double blind placebo controlled RCT-the UK National Pomi-T Study. Support Care Cancer. 2013;21:S33–4.
Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, Dobs AS, DeWeese T, Carducci M, Basaria S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol. 2009;182:2265–73.
Caso J, Masko EM, Ii JAT, Poulton SH, Dewhirst M, Pizzo SV, Freedland SJ. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate. 2013;73:449–54.
Westerlund A, Steineck G, Balter K, Stattin P, Gronberg H, Hedelin M. Dietary supplement use patterns in men with prostate cancer: The Cancer Prostate Sweden Study. Ann Oncol. 2011;22:967–72.
Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013;64:159–66.
Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63:709–16.
Ziaran S, Goncalves FM, Sn JB. Complex metabolic and skeletal changes in men taking long-term androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:33–8.
Lebret T, Coloby P, Descotes JL, Droupy S, Geraud M, Tombal B. Educational tool-kit on diet and exercise: Survey of prostate cancer patients about to receive androgen deprivation therapy. Urology. 2010;76:1434–9.
Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10:6–20.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Goonewardene, S.S., Persad, R. (2018). Results. In: Prostate Cancer Survivorship . Springer, Cham. https://doi.org/10.1007/978-3-319-65358-7_115
Download citation
DOI: https://doi.org/10.1007/978-3-319-65358-7_115
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65357-0
Online ISBN: 978-3-319-65358-7
eBook Packages: MedicineMedicine (R0)